A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Safety And Efficacy Of Efruxifermin (EFX) In Subjects with Non-Cirrhotic Non-alcoholic Steatohepatitis (NASH) And Fibrosis